Your age, family history, lifestyle, previous health information and other relevant factors can tell a different story about your cancer risk. Nova Precision AI brings these signals together into a human-centred, AI-powered screening pathway - designed around you, not just one test.
Cancer screening is not one universal package. Different cancers have different evidence, screening tests, age ranges and risk groups. Nova’s approach is to bring the relevant patient information together first, then help identify the screening pathway that needs discussion with a clinician.
Screening looks for signs of cancer or pre-cancer in people who may not have symptoms. A screening result is not the same as a diagnosis.
Used before symptoms appear to identify people who may need a particular screening test or closer evaluation
If symptoms or an abnormal screening result are present, diagnostic tests may be needed to find out what is actually happening
An abnormal result does not automatically mean cancer. Appropriate follow-up may include repeat testing, imaging, examination or biopsy
AI can help organise complex information and identify patterns. It should support - not replace - clinical judgement.
Capture age, sex, family history, lifestyle, previous conditions and relevant clinical information
AI-assisted analysis organises relevant risk signals into an understandable patient profile
Identify screening or surveillance options that may be relevant to your risk group
Results are interpreted in context rather than viewed as isolated numbers or reports
Know what to discuss, what may need follow-up and when clinical review is appropriate
Not every cancer has a routine screening test for people at average risk. Some pathways are intended only for selected high-risk groups.
Screening can find breast cancer before a person notices symptoms. The right test and interval depend on age, risk and local guidance
Cervical screening looks for HPV infection and/or abnormal cervical cells before cancer develops
Screening can detect colorectal cancer early and can also identify precancerous polyps
Low-dose CT is used for lung cancer screening in selected people at increased risk, particularly based on age and smoking history
PSA-based screening is not a one-size-fits-all test. The potential benefits and harms should be discussed with a clinician
Regular surveillance is relevant to selected people with chronic liver disease or other recognised high-risk conditions
There is no established universal screening test for all asymptomatic adults. Suspicious oral or head/neck changes should be assessed promptly
Routine screening is not recommended for average-risk people. Surveillance may be considered in selected hereditary or familial high-risk groups
For women at average risk without symptoms, routine screening with CA-125 or ultrasound has not been shown to provide a net benefit
Routine whole-population screening is not established. Knowing your skin and getting suspicious changes checked can be important
Routine screening recommendations vary substantially by country and baseline risk. Some high-incidence regions have organised programmes
Routine screening of asymptomatic adults is not generally recommended. A thyroid lump or concerning symptom needs clinical assessment
A useful risk profile brings together the information that may change what screening or clinical assessment is appropriate.
Screening is generally designed for people without symptoms. If you notice a persistent lump, unexplained bleeding, blood in stool or urine, a persistent cough or voice change, unexplained weight loss, a changing mole, difficulty swallowing, or another concerning change, seek medical advice rather than waiting for a screening appointment.
Nova Precision AI describes its approach as personalised, precision-driven cancer care and provides screening and navigation services. This page translates that philosophy into a patient-friendly screening experience.
Relevant information can be structured and analysed to help create a clearer risk-informed view
Screening choices, abnormal findings and next steps require appropriate clinical judgement
The goal is not simply to order tests - it is to help patients understand what the result means and what may come next
Build a clearer picture of your personal risk factors and discuss the right screening pathway with a qualified healthcare professional.
